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T he aim of this commentary is to document our experience andlessons learned of running a randomized controlled trial (RCT)
in vulvar erosive lichen planus (ELPV), an uncommon and
underresearched condition. Vulvar erosive lichen planus causes
painful vulvovaginal erosions, which affect daily function and qual-
ity of life.1 Response to standard first-line therapy (superpotent
topical corticosteroids) is often inadequate, and there are no RCTs
to guide second-line treatment.2 The “hELP” (Systemic Therapy
for Vulvar Erosive Lichen Planus) trial was a pilot study to assess
feasibility of a definitive trial comparing systemic treatments for
ELPV. Ethical approval (14/YH/0046), prospective trial registra-
tion (ISRCTN: 81883379), and protocol publication3 occurred.
“hELP”was amulticenter, four-arm, assessor-blind, pilot RCT
recruiting from 12 UK sites for 14 months. Eligible participants
were randomized to a 6-month course of hydroxychloroquine,
methotrexate, or mycophenolate mofetil or a 4-week reducing
regimen of prednisolone (comparator group); all received super-
potent topical corticosteroids.
Inclusion criteriawere the following: women older than 18 with
a clinical diagnosis of moderate to severe ELPV, despite 3-month
treatment with clobetasol propionate 0.05%, plus documented vulvar
biopsy that excluded malignant/premalignant disease. Participants
must have agreed to clinical photographs.
Exclusion criteria were the following: (1) lichen sclerosus/
lichen planus overlap; (2) received any of the systemic trial drugs
within the lastmonth; (3) a previous or current diagnosis ofmalignant
disease; (4) premalignant cervical or vulvar disease; (5) live vaccine
administration in the last 2 weeks; (6) pregnancy or breastfeeding;
(7) allergy to any of the trial medications; (8) history of clinically sig-
nificant renal/liver impairment or concurrent medications that
would interact with the trial drugs; and (9) any other reason that
the trial medications would not be given in usual clinical practice.
Feasibility outcomes were the proportion of eligible partici-
pants randomized; the proportion of patients adhering to treatment,
quality and suitability of clinical images, suitability of trial design,
and suitability of clinical outcomes. The primary clinical outcome
was treatment “success” at 6months. Because of the absence of val-
idated outcomemeasures for ELPV, the definition of “success”was
agreed after qualitative work with expert clinicians.4 Treatment was
classed as successful if both the following outcomes were met:
1. Patient global assessment of disease severity of “none” or “mild”
(on a 4-point scale of none, mild, moderate, or severe disease).
2. Any improvement from baseline judged by blinded assessment
of clinical photographs.
The trial was pragmatically designed; interventions were
tested in an environment that was as close to real-life as possible
in terms of setting, study population, intervention, comparator,
and outcomes.5
Of 180 patients screened, only 44 (24%) were eligible. Inel-
igibility reasons are in Figure 1. Of those eligible, 22 (50%) of
44 were randomized; 20 did not consent to take a tablet treatment.
The studywas closedwithout reaching its recruitment target of 40.
For those 22 patients who entered the trial, study medications were
not started by four participants, four stopped trial treatment early
and two were lost to follow-up (Figure 1).
Only 14 of 22 participants had complete before and after im-
ages, and overall quality was poor despite being taken by medical
photography. Treatment “success” only occurred in the hydroxychlor-
oquine (2/6, 33%) and mycophenolate mofetil (2/5, 40%) groups.
hELP was an ambitious trial because it was looking to recruit
patients with an uncommon skin condition for second-line treat-
ment. However, preliminary data had suggested that the recruit-
ment target was achievable. The lessons learned are summarized
in Table 1, and specific lessons learned for future ELPV trials
are expanded upon hereinafter.
Despite 180 patients being identified, many were not eligible.
The main ineligibility reason was mild disease. In counseling po-
tential participants for hELP, some were found to not be using top-
ical steroids effectively; re-education on topical treatment, for some,
led to better disease control and negated the need for systemic ther-
apy. This suggests that over time, patients' technique of applying
and understanding of the importance of topical treatments was less-
ening and not being regularly assessed by clinical care teams.
Of those eligible, the main reason for nonparticipation was
that people did not want to take a tablet treatment, despite clini-
cally moderate/severe disease. People with ELPV are often of an
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older age group, likely to have comorbidities and be more anxious
about combining medications or adverse effects. This should be
borne in mind for future trials as reluctance for systemic therapy
may always present a barrier to recruitment.
Patient-reported symptoms are a guide for therapeutic decision-
making4 and are arguably the most important outcome to mea-
sure. However, because this was an open-label trial, we wanted
to ensure a blinded component to the clinical end point through
using objective assessment of clinical photographs. Only four
participants achieved our definition of “treatment success.” How-
ever, 10 of 16 showed improvement in patient global assessment
and 6 of 16 continued treatment after 6 months. This suggests that
the composite primary outcomewas too stringent and a set of “core
outcome measures”6 is essential to success of future ELPV trials.
Despite clinical photography being usual practice in the man-
agement of vulval disease, the concept of taking images deterred 2
(4%) of 44 of eligible patients from consenting to the study. In ad-
dition, 6 (46%) of 13 contacted at 12months stated that they found
the photographs embarrassing or that they were not keen on hav-
ing them taken.
Photographs received were of varying quality, despite the pro-
vision of a standardized photographic protocol. Medical imaging
provision varied widely between centers. Some had photographers
present in the clinic who could take the images immediately. Others
only operated at specific times, often in a different location within
the hospital. The latter led to practical difficulty, especially if im-
ages needed to be retaken because of inadequate initial images.
Important lessons applicable to developing and delivering fu-
ture trials have been learned by conducting the hELP study. Run-
ning a pilot trial was an important step to assess feasibility and in
this case stopped a full-scale RCT from proceeding. Valuable re-
sources have therefore been saved, and we hope that the lessons
learned will prevent future research waste in other areas.
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TABLE 1. Lessons Learned From the hELP Study: The Lessons Learned Have Been Categorized and Potential Solutions Suggested to
Inform Other Researchers' Trial Designs
Problem identified Potential solution
Trials of rare conditions Small patient numbers Screen all patients as every patient counts and may
potentially be eligible, if not now, at a later stage
Identified patients ineligible for trial Trial design should allow flexibility to re-approach
patients on the screening log if initially they were
not eligible but subsequently meet eligibility criteria
(especially important for relapsing-remitting conditions)
Study profile loses prominence as each
site only recruits a few patients
Teams need to feel a sense of ownership and responsibility
for the study. Regular communication and feedback
with recruiting sites maintains momentum and keeps
study profile prominent.
Rare conditions are often only managed
in specialist setting
Engaging with wider clinical networks is essential in
terms of identifying and referring potential participants
to recruiting sites
Multiarmed studies PIL lengthy and may be confusing to patients Consider an initial summary leaflet in advance of the full
patient information leaflet
Eligibility criteria may be particularly
restrictive especially in certain patient
populations, e.g., older people.
Patient involvement in trial design will be key in establishing
whether people will be willing to enter the study
Trials for ELPVand vulval
skin conditions
Better use of topical treatment improved
disease control for some participants
Ensure regular assessment of patient's technique and
understanding of importance of topical treatment application
No validated outcome measures A set of internationally agreed core outcome measures
would ensure the most appropriate outcome measure
tools would be used in future studies
Significant variation between sites in
quality of clinical photographs
Clinical services could be enhanced by the standardization
of use of photographs to monitor patients
Not all patients consent to photographs
being taken even when anonymous
Photographs should be part of usual clinical care for
monitoring purposes. Standardization of vulval services
to include regular clinical imaging would make patients
feel more comfortable about having photographs taken
Specialty clinics run infrequently Ensure that funding for research visits is available, even for
pragmatic studies, to allow flexibility for patients when
clinic appointments are far apart
Journal of Lower Genital Tract Disease • Volume 00, Number 00, Month 2018 Lessons Learned from the “hELP” Trial
© 2018, ASCCP 3
Jennifer Ross (RN), Bibi Badal (RN), Adebanke Aboaba (RN) Dr.
Ekeowa-Anderson (CoI), Dr. Clare Marshall (CoI), Dr. Anthony
Hollingworth (CoI), Satwinderjit Shinhmar (Co-I); St Mary's
Hospital, Central Manchester University Hospitals NHS Foun-
dation Trust: Dr. Ursula Winters (PI), Dr. Christina Wong
(CoI), Rebecca Leech (RN); Salford Royal Hospital, Salford
Royal NHS Foundation Trust: Dr. Christina Wong (PI), Dr.
Vikram Rajkomar (CoI).
REFERENCES
1. Lundqvist EN, Wahlin YB, Bergdahl M, et al. Psychological health in
patients with genital and oral erosive lichen planus. J Eur Acad Dermatol
Venereol 2006;20:661–6.
2. Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus
affecting mucosal sites. Cochrane Database Syst Rev 2012;CD008092.
3. Simpson RC, Murphy R, Bratton DJ, et al. Systemic therapy for vulval
Erosive Lichen Planus (the 'hELP' trial): study protocol for a randomised
controlled trial. Trials 2016;17:2.
4. Simpson RC, Thomas KS, Murphy R. Vulval Erosive Lichen Planus:
A qualitative investigation of U.K. clinician views and principles of
management. Br J Dermatol 2013;169:226–7.
5. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory
continuum indicator summary (PRECIS): a tool to help trial designers. J Clin
Epidemiol 2009;62:464–75.
6. Foster DC, Stockdale CK, Simpson R, et al. Core Outcome Sets for Clinical
Trials and Observational Studies in Vulvovaginal Disease. J Low Genit Tract
Dis 2017;21:163–5.
Simpson et al. Journal of Lower Genital Tract Disease • Volume 00, Number 00, Month 2018
4 © 2018, ASCCP
